标志着全球医疗科技新篇章的盛大路演，将于2024年12月7日在洛杉矶四季广场隆重举行！Sonablate这家公司作为全球超声聚焦无创治疗前列腺疾病的佼佼者，将为大家震撼展示其颠覆性技术和未来无限可能。作为60多个国家的首选，Sonablate已成功治愈超过六万名患者，背后18年强有力的临床数据彰显其不容置疑的行业领导地位。
The grand roadshow marking a new chapter in global medical technology will take place on December 7, 2024, at the Four Seasons Plaza in Los Angeles. Sonablate, a world leader in non-invasive focused ultrasound treatment for prostate conditions, will unveil its groundbreaking technology and the limitless future it promises. Recognized as the premier choice across more than 60 countries, Sonablate has successfully treated over 60,000 patients, supported by 18 years of robust clinical data that underscores its undisputed leadership in the industry.
改变未来的创新力量
The Innovative Force Shaping the Future
Sonablate公司致力于通过创新技术改变未来医疗，为患者提供安全高效的治疗方案，重塑未来肿瘤治疗版图，抢占亿万市场。公司的核心业务专注于已获得FDA、CE和NMPA批准的前列腺癌及肥大治疗，商业模式独具一格。面对美国超过300万前列腺癌症患者及每年新增的30万病例，加上高达1500万前列腺肥大的庞大市场，Sonablate瞄准这一巨大的市场需求并解决市场痛点，通过设备投放与利润共享的方式，与北美最大流动医疗运营商Agiliti合作，计划在未来24个月内部署150台设备，目标是到2026年实现3万名患者的治疗，签约1500名泌尿科医生，覆盖1000家医院。
Sonablate is dedicated to transforming the future of healthcare through cutting-edge technology, providing precise, non-invasive, safe and efficient focal treatment solutions that target multi-billion-dollar markets. The company’s core business focuses on FDA, CE, and NMPA-approved treatments for prostate cancer and benign prostatic hyperplasia, supported by a unique business model. Addressing the substantial market demand from over 3 million patients in the U.S. and 300,000 new cases annually as well as vast BPH market with over 15M patients, Sonablate is set to revolutionize this landscape. Through a strategic partnership with Agiliti, the largest mobile medical service operator in North America, Sonablate plans to deploy 150 devices over the next 24 months. By 2026, the company aims to treat 20,000 to 30,000 patients, engage 1,500 urologists, and collaborate with 1,000 hospitals.
Sonablate拥有颠覆传统治疗的差异化优势。公司的HIFU技术依托专利保护，从核心换能器的独有材料，到美国自研自制的操作系统和关键硬件，建立了强劲的技术壁垒，确保足够高的技术门槛让竞争对手无法跨越。此外，Sonablate拥有专属的AI robotic手术系统，通过智能规划精准治疗路径，实时监测并提供三色安全反馈，达到无创治疗的卓越效果。这些技术优势使Sonablate在市场上脱颖而出，彻底改变了传统手术的风险与不便，为患者提供更为理想的无创治愈选择，迅速成为现代社会追求高生活质量趋势下的全球首选。
Sonablate boasts a differentiated advantage that disrupts traditional treatment methods. The company’s High-Intensity Focused Ultrasound (HIFU) technology is bolstered by strong patent protection, covering everything from the proprietary materials used in its core transducer to the domestically developed operating and manufactured technology in the United States. This creates formidable technological barriers that raises the bar to the zenith. Furthermore, Sonablate has developed an exclusive AI-assisted robotic surgical system that intelligently plans precise treatment paths, provides real-time monitoring, and delivers safety feedback through a three-color system, ensuring superior outcomes in non-invasive treatments. These technological strengths make Sonablate stand out in the market, transforming the risks and inconveniences associated with conventional surgery. By offering an ideal, non-invasive cure, Sonablate has quickly become the global treatment of choice, aligning with modern society’s growing emphasis on high-quality living standards.
前沿科技与智能医疗的完美结合
The Perfect Integration of Advanced Technology and Intelligent Healthcare
Sonablate的AI HIFU技术开创了无限可能，展现了前沿科技与智能医疗的完美结合。公司不仅拥有热消融和机械振动气化消融的双重技术优势，还不断将技术扩展到甲状腺结节、乳腺肿瘤、脑卒中后遗症, 睡眠呼吸暂停，口腔癌，食道癌，肝癌，胰腺癌，直肠癌，宫颈癌等多种病症。未来，Sonablate计划结合LOFU/LIFU技术，助力CAR-T细胞优化和免疫疗法，进一步覆盖更多临床应用。
Sonablate’s AI-driven robotic HIFU technology unlocks limitless possibilities, exemplifying the perfect fusion of cutting-edge technology and intelligent healthcare. The company harnesses dual technological advantages of thermal ablation and mechanical cavitation ablation, continually expanding its capabilities to treat a wide range of conditions, including thyroid nodules, breast tumors, and post-stroke complications, sleeping apnea, oral cancer, esophageal cancer, liver cancer, pancreas cancer, rectal cancer, cervix cancer etc. Looking forward, Sonablate aims to integrate LOFU (Low-Intensity Focused Ultrasound) and LIFU (Low-Intensity Focused Ultrasound) technologies to enhance CAR-T cell optimization and immunotherapy, extending its impact across broader clinical applications.
Sonablate设备采用AI算法，能够实时监测治疗效果，并为医生提供“绿-黄-橙”的安全反馈，确 保每次治疗的精准与安全并重，实现智能诊疗的实时掌控。这些创新技术不仅提升了疗效，还确保了治疗过程中的安全性，为患者提供更加理想的治疗体验。
Sonablate’s devices leverage advanced AI algorithms to monitor treatment outcomes in real-time, providing physicians with safety feedback in “green-yellow-orange” signals. This system ensures a balanced focus on both precision and safety for each procedure, enabling real-time, intelligent control of the therapeutic process. These innovative technologies not only enhance treatment efficacy but also ensure safety throughout the procedure, offering patients an optimized and superior treatment experience.
在全球战略布局上，Sonablate同样展现出创新的商业模式。在中国，Sonablate与本地合作伙伴合资，迅速推进市场普及；在北美和英国，Sonablate通过设备投放和利润共享的方式，助推HIFU技术的加速普及。同时，美国Medicare/Medicaid已批准收费标准，进一步降低了患者的治疗成本，提高了技术的覆盖率。通过这些举措，Sonablate正在开创医疗商业的新模式，为更 多患者提供安全、有效、无创的治疗选择。
In its global strategic expansion, Sonablate demonstrates an innovative business model. In China, the company has formed joint ventures with local partners to accelerate market penetration. In North America and the UK, Sonablate has adopted a strategy of equipment placement combined with profit-sharing to accelerate the adoption of HIFU technology. Additionally, Medicare/Medicaid in the United States has approved reimbursement rates, significantly reducing treatment costs for patients and enhancing the accessibility of the technology. Through these initiatives, Sonablate is pioneering a new model for medical commercialization, providing safe, effective, and non-invasive treatment options to a broader patient population.
重量级嘉宾阵容-共探数字平台化医疗未来
Headline: Esteemed Guest Lineup - Exploring the Future of Digital Platform-Based Healthcare
特邀嘉宾- Special Guests
• Richard Yang杨华东，Sonablate主要投资人兼CEO
• Dr. Lingyun Xiang，新兴产业金融专家，FCPA，HKICPA，FAIA，FIPA
• Dr. Jonathan Zhang，WWTH律师事务所主任，多家纳斯达克与NYSE上市公司独立董事
医学界大咖：
• Dr. Wuwei Feng冯武威教授，杜克大学医学院脑血管病主任，高级卒中中心主任
冯武威教授是一位在卒中康复和脑刺激领域享有盛誉的临床医生科学家，目前正在主持NIH, AHA/ASA等资助的大型多中心临床研究项目。
Dr. Wuwei Feng is a renowned clinician-scientist in the field of stroke rehabilitation and brain stimulation. He is currently leading large, multi-center clinical research projects funded by the NIH and the American Heart Association/American Stroke Association (AHA/ASA).
• Dr. Yingxiao Wang王英晓教授，南加州大学生物医学工程系主任，CAR-T细胞专家
王英晓教授在生物传感器和免疫细胞工程领域成就卓著，现致力于研发基于超声波控制的CAR-T细胞和巨噬细胞等免疫细胞进行肿瘤治疗的创新技术。
Dr. Yingxiao Wang has made outstanding contributions in the fields of biosensors and immune cell engineering. He is currently focused on developing innovative technologies for tumor treatment using ultrasound-controlled CAR-T cells and macrophages.
• Dr. Narendra Sanghvi，Sonablate创始人兼首席科学家，印第安纳大学医学院教授
Dr. Sanghvi 是高强度聚焦超声（HIFU）技术领域的先驱，曾在印第安纳大学医学院担任副教授和资深研究科学家，并在超声治疗技术及其标准化领域有卓越贡献。
Dr. Sanghvi is a pioneer in the field of High-Intensity Focused Ultrasound (HIFU) technology. He has served as an Associate Professor and Senior Research Scientist at the Indiana University School of Medicine, making exceptional contributions to the advancement and standardization of ultrasound therapeutic technologies.
• Dr. Naiem Nassiri，耶鲁大学医学院教授，新英格兰血管疾病中心医院专家Dr. Nassiri专注于复杂性主动脉病变的腔内及杂交手术治疗、颅外脑血管重建和血管畸形的综合治疗，并于2021年在耶鲁纽黑文医院成功实施了该院首例腔内分支型胸腹主动脉瘤手术。
Dr. Nassiri specializes in endovascular and hybrid surgical treatments for complex aortic pathologies, extracranial cerebrovascular reconstruction, and comprehensive management of vascular malformations. In 2021, he successfully performed the first endovascular branched thoracoabdominal aneurysm repair at Yale New Haven Hospital.
活动时间与地点
• 时间: 2024年12月7日，上午9:00至下午5:00
• 地点: 18558 Gale Ave, #338, City of Industry, CA 91748, 四季广场3楼 (Seasons Place 3rd Floor)
结语
这是一次医疗科技与金融资本的绝妙碰撞，Sonablate将携前沿技术引领全球医疗变革。无创治疗的未来已经到来，我们诚邀您亲临体验，见证这一历史时刻！
This is a remarkable convergence of medical technology and financial capital, where Sonablate will lead a global revolution in healthcare with its cutting-edge innovations. The future of non-invasive treatment has arrived, and we warmly invite you to join us in person to witness this historic moment firsthand.
了解更多详情，请访问（rsvp连接）For more information, please visit:
